This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Regenerative Medicine Markets


Figure 2.1: Geographic Distribution of Tissue Engineering Firms in Major Markets 32Figure 2.2: The Potential Uses of Embryonic Stem Cells 33Figure 2.3: Progress of Cell Therapy Product Research, 2012 34Figure 2.4: Commercially Available Cell Therapy Products, 2012 35Figure 2.5: Disease Focus by Regenerative Medicine 39Figure 2.6: Estimated Completion Dates for Stem Cell Based Clinical Trials Targeting Type 1 Diabetes, 2009-2015 45Figure 2.7: Number of Clinical Trials by Targeted Condition, 2005-2011 45Figure 2.8: Concentration of European Cell Therapy Firms, 2012 46Figure 2.9: European Stem Cell Platforms by Cell Source 47Figure 2.10: Autologous vs. Allogeneic Stem Cell Therapy Firms in Europe, 2012 48Figure 2.11: Autologous and Allogeneic Somatic Cell Therapy Firms in Europe, 2012 48Figure 2.12: Sponsors of Cell Therapy Clinical Trials in the U.K., 2012 52Figure 2.13: Clinical Trials Involving Allogeneic vs. Autologous Cell Therapy Products in the U.K., 2012 52Figure 2.14: Cell Types Involved in the U.K. Cell Therapy Clinical Trials, 2012 53Figure 2.15: U.K. Cell Therapy Clinical Trials by Indication, 2012 54Figure 2.16: Cell Culture Products Market by Segment, 2012 55Figure 2.17: Market for Reagents Used in Cell Culture, 2012-2019 56Figure 2.18: Market for Media Used in Cell Culture, 2012-2019 57Figure 2.19: Market for Serum Used in Cell Culture, 2012-2019 58Figure 5.1: CIRM's Grants for Disease Types by Funding Level, 2012 110Figure 7.1: Commercially Available Regenerative Products 119Figure 7.2: Global Market for Tissue Engineering Products, 2012-2019 123Figure 7.3: Global RM Market for Cardiology and Vascular Products, 2012-2019 126Figure 7.4: Alternatives for Medtronic's Infuse 128Figure 7.5: Global Market for RM Products in Orthopedics, Musculoskeletal and Spine, 2012-2019 130Figure 7.6: Global RM Market for Neurology Products, 2012-2019 131Figure 7.7: Global RM Market for Dental Products, 2012-2019 132Figure 7.8: Global Tissue Engineering and Cell Therapy Market for Cancer Products, 2012-2019 133Figure 7.9: Global Market for RM Products in Urology, 2012-2019 134Figure 7.10: Global Market for RM Products in Skin/Integument, 2012-2019 135Figure 7.11: Global Tissue Engineering and Cell Therapy Market, 2012-2019 136Figure 7.12: U.S. Market for Tissue Engineered Skin Replacement and Substitutes, 2012-2019 137Figure 7.13: U.S. Market for RM Products in Orthopedic/Spine, 2012-2020 139Figure 7.14: U.S. Market for RM Products in Nerve Repair, 2012-2020 140Figure 7.15: U.S. Market for RM Products in Cardiovascular Therapies, 2012-2020 141Figure 7.16: U.S. Market for RM Products in Anti-Inflammatory Therapies, 2012-2020 142Figure 7.17: U.S. Market for RM Products in Diabetes, 2012-2020 143Figure 7.18: U.S. Market for Regenerative Medicines, 2012-2020 144Figure 7.19: U.S. Regenerative Medicine Market by Segment, 2020 145Figure 8.1: Global Market for Stem Cell Products, 2012-2020 148Figure 8.2: U.S. Market for Stem Cell Products, 2012-2020 151Figure 8.3: Estimated U.S. Market for Stem Cell Therapy by Type, 2020 153Figure 8.4: European Market for Stem Cell Products, 2012-2020 153Figure 8.5: Number of Autologous and Allogeneic Cell Therapy Firms in Europe 154Figure 8.6: Asia-Pacific Market for Stem Cells, 2012-2019 155Figure 8.7: Global Autologous Cell Therapy Market, 2012-2019 156Figure 9.1: Cell-Based Business Models 159Figure 9.2: Current Autologous Business Models 161Figure 9.3: Current Allogeneic Business Models 162Figure 10.1: Aastrom's Cell Expansion Process 167


Table 2.1: Commercially Available Bioengineered Skin Products 23Table 2.2: A Partial List of Companies Offering Bioreactor Systems 25Table 2.3: Number of Tissue Engineering Companies in the Five Focus Countries 28Table 2.4: Number of Tissue Engineering Firms Developing Stem Cells Seeded to Scaffolds 28Table 2.5: Number of Tissue Engineering Firms Focusing on Skin, Cartilage, Bone and Urological Products 29Table 2.6: Number of Tissue Engineering Firms Focused on Cardiovascular Products 30Table 2.7: Number of Tissue Engineering Firms Focusing on Neurological Products 30Table 2.8: Number of Tissue Engineering Firms Focusing on Pancreas, Liver and Kidney 31Table 2.9: Number of TE Firms Focused on Autologous and Allogenic Products 31Table 2.10: Major Cell Therapy Companies 36Table 2.11: Geographical Distribution of Cell Therapy Companies 38Table 2.12: Cell Therapy Products on the Market 40Table 2.13: Cell Therapy Products on the Market by Type and Application 40Table 2.14: Potential Patients for Cell Therapy in the U.S. 41Table 2.15: Number of Patients Treated with Cell Therapy Between 1988 and 2010 42Table 2.16: Cell Therapy Pipeline, 2005-2011 42Table 2.17: Number of Stem Cell Clinical Trials by Indication, 2012 43Table 2.18: Major Cell Therapy Clinical Trials for Diabetes and Estimated Enrollment Targets, 2012 44Table 2.19: Progress in Clinical Trials for Diabetes, 2012 44Table 2.20: Cell Therapy Deals, 2007-2011 49Table 2.21: Select Cell Therapy Products with FDA/EMA Regulatory Approval, 1998-2010 50Table 2.22: Cell Therapy Companies and Products 50Table 2.23: Cell Therapy Products Approved in South Korea 51Table 2.24: Selected Suppliers of Culture Media and Reagents 58Table 2.25: Selected Suppliers of In Vitro Te

To order this report: Blood_Supply,_Tissue_Banking_and_Transplantation Industry: Regenerative Medicine Markets

Contact: Nicolas BombourgReportlinkerEmail: nicolasbombourg@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TSLA $233.78 -3.30%
YHOO $36.06 -1.30%
AAPL $94.16 0.56%
FB $117.96 -0.51%
GOOG $695.89 -0.33%


Chart of I:DJI
DOW 17,701.19 -189.97 -1.06%
S&P 500 2,058.43 -23.00 -1.10%
NASDAQ 4,759.1050 -58.4890 -1.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs